EMZ 702

Drug Profile

EMZ 702

Alternative Names: EMZ-702; EMZ702 + peginterferon-α + ribavirin; HCV-I.E.T.; HCV-IET; Interferon Enhancing Therapy for hepatitis C - Transition Therapeutics; Pegylated interferon-α + ribavirin + EMZ702

Latest Information Update: 08 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transition Therapeutics
  • Class Antivirals; Interferons; Ribonucleosides
  • Mechanism of Action Enzyme inhibitors; Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Aug 2006 Final results from a phase I/II clinical trial in patients with Hepatitis C have been added to the adverse events and Viral Infection therapeutic trials sections
  • 28 Apr 2006 Interim results from a phase I/II clinical trial in patients with Hepatitis C have been added to the Viral infections therapeutic trials section
  • 29 Jul 2005 Phase-I/II clinical trials in Hepatitis C treatment in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top